logo color s and clearside.jpg
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
November 22, 2022 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board
November 16, 2022 04:00 ET | AKAMPION
- Former Head of Novartis' Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 --- Dopavision, a...
Global Diabetic Retinopathy Market
Outlook on the Diabetic Retinopathy Global Market to 2027 - Rising Number of Diabetic Patients is Driving Growth
November 14, 2022 04:13 ET | Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast,...
Global Ophthalmic Ultrasound Systems Market
Global Ophthalmic Ultrasound Systems Market Report 2022: Featuring Sonomed Escalon, Appasamy Associates, Nikon, DGH Technology & More
November 11, 2022 05:23 ET | Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Global Ophthalmic Ultrasound Systems Market - Forecast 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.The global ophthalmic...
logo color s and clearside.jpg
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 07:15 ET | Clearside Biomedical, Inc.
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...
OASIS Demographics and Wet AMD History
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
November 09, 2022 07:05 ET | Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
GMILogo_Vertical-Gradient.png
Ambulatory Surgical Centers Market to hit USD 144.5 billion by 2032, says Global Market Insights Inc.
November 09, 2022 05:10 ET | Global Market Insights Inc.
Selbyville, Delaware, Nov. 09, 2022 (GLOBE NEWSWIRE) -- The ambulatory surgical centers market value is estimated to exceed USD 144.5 billion by 2032, according to a new research report by Global...
logo color s and clearside.jpg
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
November 08, 2022 16:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
nacuity-pharmaceuticals-inc.jpg
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley
November 08, 2022 09:00 ET | Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other...
dry-eye-treatment-devices-market-size.jpg
Global Dry Eye Treatment Devices Market Report 2022: High Incidence & Prevalence of Dry Eye Diseases Boosting Sector
November 08, 2022 06:48 ET | Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast,...